Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc.（ITCI）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
itci · 股价预测 · 23 位分析师（近3月）· FMP · 更新于 2025年5月21日
分析师评级与共识
基于过去 3 个月内 23 位华尔街分析师
Buy
23 位分析师
共识
评级分布
12 个月目标价
High
$132
Consensus
$98.50
-25.3% upside
Low
$70.00
Median: $101.5 · Last Close: $131.87
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$98.50
-25.3% upside
High Target
$132
0.1%
Low Target
$70
-46.9%
Current Price
$131.87
as of today
Based on analyst price targets, the ITCI stock price prediction for the next 12 months ranges from $70 to $132. The consensus ITCI price forecast of $98.50 implies -25.3% upside from the current price of $131.87.
短期股价预测
Bull算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $131.74 | ↓ 0.10% |
1-day model range: $131.59–$131.89. Peak: $131.89 (-0.10%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $136 | +2.8% |
| 2028 | $138 | +4.6% |
| 2029 | $140 | +5.8% |
| 2030 | $141 | +6.6% |
| 2031 | — | +7.1% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ITCI · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-04-02 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2025-02-24 | Mizuho | Downgrade ↓ | Outperform→Neutral |
| 2025-02-21 | Needham | Maintains | Hold→Hold |
| 2025-01-31 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2025-01-22 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2025-01-14 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2025-01-13 | Needham | Downgrade ↓ | Buy→Hold |
| 2024-11-04 | JP Morgan | Maintains | Overweight→Overweight |
| 2024-10-31 | Needham | Maintains | Buy→Buy |
| 2024-10-30 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Intra-Cellular Therapies, Inc. (ITCI) stock. Of the recent 178 rating actions, 7 were upgrades and 21 were downgrades. 23 analysts currently cover ITCI.
分析师推荐趋势
ITCI analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$926M
↓ 53.3% YoY
Revenue Next Year
$1.4B
↑ 54.7% YoY
EPS This Year
$0.80
EPS Next Year
$4.31
↑ 440.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast ITCI EPS of $0.80 for the current fiscal year, based on estimates from 7 analysts. The ITCI revenue forecast is $926M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
ITCI 股价预测由两类独立数据源支撑：来自 23 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。ITCI 的共识目标价为 $98.50（-25.3% 上行空间），分析师共识为 Buy。
ITCI 的短期预测（明日）为 $131.74（-0.10%）。 ITCI 对 2027 年的股价预测均值为 $136。 ITCI 对 2030 年的预测区间为 $139–$142。
Intra-Cellular Therapies, Inc. 在 NASDAQ 上市，代码 ITCI。ITCI 在 2027 年的整体展望偏积极，在覆盖分析师中约 61% 对应 Buy 共识。
常见问题
ITCI 预测 · 8 个问题根据 23 位华尔街分析师，ITCI 的 12 个月平均目标价为 $98.50，最高 $132.00、最低 $70.00。若有图表，中位目标价可在上方查看。相对当前价 $131.87，隐含约 -25.3% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.